Quant Biomarkers AG

Quant Biomarkers AG is a Swiss life science company founded in 2021 and based in Basel that specializes in developing biomarker technologies and AI-driven solutions for the cardio-kidney-metabolic (CKM) disease spectrum. Its primary technological portfolio includes RenoRisk, a urine-based biomarker panel designed for early detection of kidney injury, and RenoPredict, an AI-powered clinical decision support system that utilizes standard blood biomarkers to assist clinicians in predicting chronic kidney disease (CKD) progression. By integrating artificial intelligence with advanced biomarker science, the company aims to move diagnostics from late-stage interventions to early, proactive risk assessment.

The company's focus addresses significant global healthcare gaps, as CKD remains widely underdiagnosed until advanced stages. By enabling earlier detection and real-time monitoring of disease progression and therapeutic response, Quant Biomarkers aims to improve clinical outcomes for patients, optimize treatment decisions for clinicians, and provide validated surrogate endpoints for drug developers. The company actively engages in translational research through strategic collaborations with academic and clinical partners, such as the Lausanne University Hospital (CHUV) and the University of Zurich (UZH), and has received non-dilutive grant funding from Innosuisse to advance its diagnostic programs.